Sophia Ran
About
In The Last Decade
Sophia Ran
73 papers receiving 6.5k citations
Hit Papers
Peers
Comparison fields: 5 of 130
- Molecular Biology 3.1k
- Oncology 2.7k
- Immunology 2.5k
- Cancer Research 1.0k
- Pulmonary and Respiratory Medicine 609
Countries citing papers authored by Sophia Ran
This map shows the geographic impact of Sophia Ran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophia Ran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophia Ran more than expected).
Fields of papers citing papers by Sophia Ran
This network shows the impact of papers produced by Sophia Ran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophia Ran. The network helps show where Sophia Ran may publish in the future.
Co-authorship network of co-authors of Sophia Ran
This figure shows the co-authorship network connecting the top 25 collaborators of Sophia Ran. A scholar is included among the top collaborators of Sophia Ran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophia Ran. Sophia Ran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 23 | |
| 5 | 14 | |
| 6 | 58 | |
| 7 | 15 | |
| 8 | 188 | |
| 9 | 131 | |
| 10 | 141 | |
| 11 | 69 | |
| 12 | 75 | |
| 13 | 70 | |
| 14 | NF-κB and Prox1 directly regulate expression of vascular endothelial growth factor receptor (VEGFR)-3 | 1 |
| 15 | Investigation of chemotherapy-induced tumor angiogenesis: Rationale for combination of nab-paclitaxel with anti-VEGF therapy | 1 |
| 16 | 17 | |
| 17 | 156 | |
| 18 | 68 | |
| 19 | 7 | |
| 20 | 213 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.